BioCardia Advances FDA Pathway for Helix Delivery Catheter

BioCardia ( (BCDA) ) has issued an announcement.

On February 10, 2026, BioCardia reported it had completed a Pre-Submission to the U.S. Food and Drug Administration under the Q-Submission program seeking approval of its Helix Transendocardial Delivery Catheter for intramyocardial therapeutic and diagnostic agent delivery. The submission draws on data from 15 well-controlled clinical trials in three primary cardiac indications and is made under the CardiAMP Cell Therapy System’s FDA Breakthrough Designation.

Company executives said they expect the Pre-Submission discussions to clarify the regulatory pathway and timing within about 45 days, potentially paving the way for a market clearance application and positioning Helix as the first approved transendocardial delivery catheter system in the U.S. Successful clearance would streamline future approvals of BioCardia’s autologous and allogeneic cell therapies and could lower development risk for biopharma partners using the Helix platform, which has shown superior safety and delivery efficiency over other cardiac delivery modalities in clinical and pre-clinical evaluations.

The most recent analyst rating on (BCDA) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.

Spark’s Take on BCDA Stock

According to Spark, TipRanks’ AI Analyst, BCDA is a Neutral.

The score is primarily constrained by very weak financial performance (no meaningful revenue, ongoing losses, and sustained cash burn), which elevates funding risk. Technicals also remain bearish with the stock below major moving averages, despite oversold signals. Positive clinical/regulatory updates and stated runway into 2026 provide some support, but do not outweigh the current financial and trend headwinds.

To see Spark’s full report on BCDA stock, click here.

More about BioCardia

BioCardia, Inc., headquartered in Sunnyvale, California, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, with a focus on cardiac indications. Its lead platforms, CardiAMP autologous and CardiALLO allogeneic cell therapies, are supported by the Helix biotherapeutic delivery catheter and the Morph steerable vascular navigation system used in minimally invasive heart procedures.

The company’s technologies target large unmet medical needs in heart failure and chronic myocardial ischemia, positioning BioCardia as both a developer of novel cell therapies and a provider of enabling delivery tools for interventional cardiologists, electrophysiologists, and cardiac surgeons. Its platforms are designed to improve targeted intramyocardial delivery, retention, and dosing of therapeutic and diagnostic agents compared with surgical or intracoronary methods.

Average Trading Volume: 77,851

Technical Sentiment Signal: Sell

Current Market Cap: $13.27M

For detailed information about BCDA stock, go to TipRanks’ Stock Analysis page.